Dehaze, a Munich-based AI copilot that unifies diverse patient health data into clean trajectories, has raised €3.2M ($3.7M) in seed funding led by YZR Capital and DN Capital. The platform uses peer-reviewed causal AI to spot outliers, overlooked diagnoses, inappropriate treatments, and future risks, delivering targeted follow-ups to clinicians and patients. The capital will expand engineering, research, and commercial teams while advancing product features like next-best actions and traceability.
European HealthTech Eyes Causal AI
Dehaze's raise coincides with growing investor interest in AI-driven chronic care solutions. Lead investor YZR Capital recently backed roclub with $11.7M and Biorce's $52M Series A, both in health and drug development AI. DN Capital, with exits like Shazam to Apple, brings scaling expertise to European AI healthtech. This blend of domain specialists and global scalers positions Dehaze for category leadership in proactive healthcare.
Fragmented Data Misses Chronic Risks
Patient health data scatters across systems, hindering early detection of chronic diseases like MS. Current approaches rely on reactive care, missing 1 in 3 undetected cases. Dehaze addresses this by harmonizing disparate records into unified trajectories, enabling AI to flag anomalies before they escalate.
Peer-Reviewed AI Delivers Insights
Dehaze's platform ingests 300M health events via 200+ algorithms, analyzing 251,276 journeys across 250k+ patient lives. Unlike general LLMs, its causal AI—peer-reviewed and published—identifies causal links for precise risk profiling. HealthPod, the consumer app, has logged 150+ users and 8,000+ chats, offering personalized insights from medical history, research, and documents.
As Marius Klages, Founder and CEO, noted:
"Our customers are global from day one… dehaze is going to define it."
Partnerships with three private health networks underscore early validation.
HealthTech Specialists Lead Round
YZR Capital, Munich-based with HealthTech focus, leads alongside DN Capital's proven track record. YZR backs ambitious founders solving healthcare challenges, like Doctor.One in chronic care paths. DN Capital adds credibility with $1B AUM and 58 exits. Local players Angel Invest, ZOHO.VC, and Better Ventures provide ecosystem support, signaling strong regional momentum for Dehaze's shift to proactive care.
Proven Founders Drive Differentiation
CEO Marius Klages brings healthtech exit experience, having sold VATION, a digital health coaching platform, in 2022. CTO Julian Matschinske holds a PhD in Computer Science from University of Hamburg and contributed to the AIMe medical AI registry. Co-founder Andreas Santoro offers serial CTO expertise. This mix of domain exits, AI research, and engineering depth fuels Dehaze's HIPAA- and EU-compliant platform.
Product Expansion Powers Growth
Funds target team growth in medical, tech, and commercial roles, plus enhancements like AI-driven next-best actions. Recent HealthPod launch targets patients and biopharma for indication awareness. Backed by University of Hamburg, University of Southern Denmark, Techstars, and Federal Ministry of Research grants, Dehaze eyes global payers to cut costs via early interventions.